4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzoic acid | 184763-33-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzoic acid
• CAS: 184763-33-5
• 化学式: C₁₁H₁₀N₂O₄
• mdl: MFCD20731085
• 分子量: 234.211
• InChiKey: GQOVIFKCRUPMQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzoic acid 在 盐酸 、 三乙胺 作用下， 以 吡啶 、 溶剂黄146 为溶剂， 反应 401.5h， 生成 (S)-alpha-甲基-4-羧基苯甘氨酸
  参考文献：
  名称：

  Resolution and regioselective protection of glutamic acid analogues. II- Synthesis, resolution and configuration assigsment of (+)-α-methyl-4-car☐yphenylglycine (M4CPG)

  摘要：

  Diastereomeric dipeptides (S)-Leu-(S)-M4CPG and (S)-Leu-(R)-M4CPG have been synthesized from (+/-)-M4CPG and separated by anion exchange chromatography. Absolute configuration of (S)-(+)-M4CPG was assigned by X-Ray crystallography of (S)-Leu-(S)-M4CPG. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0957-4166(96)00387-4
• 作为产物：
  描述：

  氰化钾 、 碳酸氢铵 、 4-乙酰基苯甲酸 以 乙醇 为溶剂， 反应 168.0h， 生成 4-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzoic acid
  参考文献：
  名称：

  Resolution and regioselective protection of glutamic acid analogues. II- Synthesis, resolution and configuration assigsment of (+)-α-methyl-4-car☐yphenylglycine (M4CPG)

  摘要：

  Diastereomeric dipeptides (S)-Leu-(S)-M4CPG and (S)-Leu-(R)-M4CPG have been synthesized from (+/-)-M4CPG and separated by anion exchange chromatography. Absolute configuration of (S)-(+)-M4CPG was assigned by X-Ray crystallography of (S)-Leu-(S)-M4CPG. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0957-4166(96)00387-4

文献信息

• Design and discovery of 2-oxochromene derivatives as liver X receptor β-selective agonists
  作者：Takayuki Matsuda、Ayumu Okuda、Yuichiro Watanabe、Tohru Miura、Hidefumi Ozawa、Ayako Tosaka、Koichi Yamazaki、Yuki Yamaguchi、Sayaka Kurobuchi、Minoru Koura、Kimiyuki Shibuya

  DOI：10.1016/j.bmcl.2015.01.047

  日期：2015.3

  an attempt to molecularly design liver X receptor (LXR) β-selective agonists, we discovered that the combination of the 2-oxochromene moiety (head) and the imidazoline-2,4-dione moiety (tail) plays an important role in the expression potency and selectivity toward LXRβ. We synthesized a series of 2-oxochromene derivatives and identified 43 as a LXRβ-selective agonist that increased the HDL-C level without

  在分子设计肝X受体（LXR）β-选择性激动剂的尝试中，我们发现2-氧代色烯部分（头部）和咪唑啉-2,4-二酮部分（尾巴）的组合在表达能力和对LXRβ的选择性。我们合成了一系列2-oxochromene衍生物，并确定了43种LXRβ选择性激动剂，可在不显着升高TG水平的情况下增加HDL-C水平，并导致高脂饮食中主动脉弓内脂质蓄积面积减少。和胆固醇喂养的Bio F 1 B仓鼠。在这份手稿中，我们报告了这些2-氧代苯并二氢吡喃衍生物的设计，合成和药理作用。
• Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20050107389A1

  公开（公告）日：2005-05-19

  The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代酰胺衍生物，其表现出对多巴胺D3受体的选择性结合。在另一个方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备上述化合物的过程，以及将这些化合物作为多巴胺D3受体成像剂的方法。
• NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3321256A1

  公开（公告）日：2018-05-16

  Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

  本发明提供了一种新型低分子量化合物，它能抑制诱导型 MMP（尤其是 MMP-9）的产生，而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式（I）代表的化合物： 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用，可作为预防和/或治疗自身免疫性疾病（如类风湿性关节炎等）、炎症性肠病（溃疡性结肠炎、克罗恩病）或骨关节炎的药物。
• Imide derivatives and use thereof as medicine
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10407408B2

  公开（公告）日：2019-09-10

  Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

  本发明提供了一种新型低分子量化合物，它能抑制诱导型 MMP（尤其是 MMP-9）的产生，而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式（I）代表的化合物： 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用，可作为预防和/或治疗类风湿性关节炎等自身免疫性疾病、炎症性肠病（溃疡性结肠炎、克罗恩病）或骨关节炎的药物。
• EP3321256
  申请人：——

  公开号：——

  公开（公告）日：——